💊FDA approves first treatment for certain patients with Erdheim-Chester Disease, a rare blood cancer. 〜 Hoffman-LaRoche, Inc.

By FDA

💊FDA approves first treatment for certain patients with Erdheim-Chester Disease, a rare blood cancer. 〜 Hoffman-LaRoche, Inc.

The U.S. Food and Drug Administration today expanded the approval of Zelboraf (vemurafenib) to include the treatment of certain adult patients with Erdheim-Chester Disease (ECD), a rare cancer of the blood. Zelboraf is indicated to treat patients whose cancer cells have a specific genetic mutation known as BRAF V600. This is the first FDA-approved treatment for ECD.
The FDA granted this application Priority Review and Breakthrough Therapy designations for this indication. Zelboraf also received Orphan Drug designation for this indication, which provides incentives to assist and encourage the development of drugs for rare diseases.
The FDA granted the approval of Zelboraf to

Hoffman-LaRoche, Inc.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm583931.htm
Roche – FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation

https://www.roche.com/media/store/releases/med-cor-2017-11-07b.htm

More from tokioX :

  1. FDA approves over-the-counter hearing aid from Bose
  2. 💊FDA PHARMA TODAY
  3. 💊FDA PHARMA today
  4. FDA approves gene therapy Luxturna for hereditary blindness
  5. 💊FDA PHARMA today
  6. 💊FDA PHARMA updates
  7. 💊the U.S. Food and Drug Administration has approved